Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience, Inc. reports clinical-stage biotechnology developments focused on metabolic health disorders, obesity and overweight. The company's lead program, nimacimab, is a peripherally restricted monoclonal antibody inhibitor of the CB1 receptor being evaluated in the CBeyond Phase 2a program, including monotherapy and combination work with GLP-1 or other incretin-based therapies.
Recurring updates cover clinical data from CBeyond, higher-dose safety and pharmacokinetic work, regulatory feedback on follow-on trial design, manufacturing and formulation activities, scientific conference presentations, financial results and corporate outlooks. Skye also discusses its broader strategy of developing molecules that modulate G-protein-coupled receptors.
Skye Bioscience (OTCQB: SKYE) announces CEO Punit Dhillon's participation in the Benzinga Biotech Small Cap Conference on March 25, 2021. He will engage in a virtual panel titled 'The Natural Solutions: Cannabis & Cannabinoids' at 11:40 AM EST and present a corporate overview named 'Unlocking the Pharmaceutical Potential of Cannabinoids' at 12:10 PM EST. The Company focuses on developing cannabinoid-derived molecules aimed at treating glaucoma and other serious diseases. Their lead candidate shows promise in lowering intraocular pressure, surpassing current treatments.
Skye Bioscience (OTCQB: SKYE) announced positive preclinical results for its THC prodrug, THCVHS, which showed no eye irritation in the EpiOcular TM MTT ET-50 assay. This non-irritating profile is vital for future clinical testing. Skye aims to develop cannabinoid-derived medicines with rigorous standards and will advance THCVHS into a Phase 1 study for glaucoma treatment anticipated in early 2022. The study's findings underscore the formulation's safety and support Skye's commitment to innovative therapeutic solutions for unmet medical needs.
Skye Bioscience (OTCQB: SKYE) announced the appointment of cannabinoid experts Giovanni Appendino, PhD, and Eduardo Muñoz, MD, PhD, to its scientific advisory board. CEO Punit Dhillon emphasized the significance of their expertise in advancing cannabinoid-based medicines. Dr. Appendino brings over 40 years of research experience, while Dr. Muñoz has significant expertise in cannabinoid pharmacology and inflammation. Their contributions aim to enhance Skye's pipeline, particularly its lead molecule targeting glaucoma, which has shown promise in preclinical studies.
Skye Bioscience, Inc. (OTCQB: SKYE) announced that CEO Punit Dhillon will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 09, 2021, at 7:00 AM EST. The company focuses on developing synthetic cannabinoid-derived molecules to treat glaucoma and other unmet medical needs. The presentation will be available on Skye's investor relations website. Skye's lead molecule shows potential in lowering intraocular pressure in glaucoma patients, offering a new therapeutic class.
Skye Bioscience, Inc. (OTCQB: SKYE) announced participation in three investment events in February 2021. CEO Punit Dhillon will present at the Small-Cap Growth Investor Conference on February 4 at 3:30 PM EST. He will also present at the Money Show February Virtual Expo on February 18 at 11:20 AM EST. VP Karam Takhar will present at the Benzinga Cannabis Capital Conference on February 25 at 10:40 AM EST. These presentations will provide insights into their innovative cannabinoid-derived therapies targeting glaucoma and other unmet medical needs.